CAMBRIDGE: Abcam plc (Nasdaq: ABCM), a global leader in the supply of life science research tools, has announced that its shareholders have approved the proposal for Danaher Corporation (NYSE: DHR) to acquire all of the outstanding shares of Abcam for $24.00 per share in cash. The deal is valued at approximately $5.8 billion.

The transaction was approved by a majority of Abcam shareholders who voted at the Court Meeting and the General Meeting held on November 6, 2023. The transaction is expected to close in the first quarter of 2024, subject to the sanction of the Scheme by the High Court of Justice of England and Wales, the satisfaction of certain antitrust conditions, and other customary closing conditions.

Abcam’s Board of Directors and CEO expressed their satisfaction with the outcome, saying that the transaction marks an exciting new chapter for Abcam and its customers, and that they look forward to joining the Danaher family and benefiting from the Danaher Business System. Danaher is a global science and technology innovator with a portfolio of businesses in the life sciences, diagnostics, and environmental and applied solutions sectors.